BioSpace News Archive

Biolexis is proud to announce the presentation of two significant abstracts at the upcoming American Diabetes Association conference on June 21-24, 2024.

Palisade Bio, Inc. today provided an update on key areas of progress for its previously announced strategic collaboration with Strand Life Sciences (“Strand”), a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis (UC) therapy.

NX Development Corp. (NXDC) is pleased to announce a significant milestone.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCD) (“BioHarvest” or the “Company”), announced today that its board of directors have approved a private placement of up to 697,350 units

Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all their health in one place, announced today that it has entered into a definitive agreement to be acquired by an affiliate of Altaris, LLC, an investment firm exclusively focused on the healthcare industry.

Researchers at the Pacific Northwest Research Institute (PNRI) and collaborating institutions have made a groundbreaking discovery that could significantly advance our understanding of genomic disorders.

Mozart Therapeutics, a clinical stage biopharmaceutical company focused on the development of CD8 Treg modulators for the treatment of autoimmune diseases, today presented new preclinical data on the Company’s lead program, MTX-101.

Findings from the Lowering Events in Non-proliferative retinopathy in Scotland Trial revealed that fenofibrate, a medication used for many years to reduce blood fat levels, significantly reduces the progression of diabetic retinopathy, a diabetes-related eye disease.

Eli Lilly and Company (NYSE: LLY) announced detailed results from the SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection (10 mg or 15 mg) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy.

Arvinas, Inc. today announced it presented new preclinical data from its investigational BCL6 PROTAC® degrader ARV-393 at the European Hematology Association (EHA) 2024 Annual Congress that took place June 13-16, 2024 in Madrid, Spain, and presented new preclinical data from its PROTAC LRRK2 degrader program at the Biennial International LRRK2 Meeting that took place June 18-21, 2024 in Crete, Greece.